After a first fundraising in 2021, Paltech SAS closed in October 2023 a new round of more than one million euros fully subscribed by private investors.

Founded by doctors Réginald Allouche and Charles-Henri Malbert in 2021, Paltech SAS is an innovative company dedicated to the research for a curative treatment for type 2 diabetes.

Type 2 diabetes is a developing disease that affects more than 800 million people worldwide. The complications induced by this disease both in medium and long terms are strongly disabling. Type 2 diabetes is notably the main cause in non-traumatic amputations, blindness, kidney failure and neuropathy. Most treatments currently available are palliative and allow individuals to live with the disease without curing it. Paltech is developing a medical device that under certain conditions might cure people with type 2 diabetes. The first experiments made it possible to validate the proof of concept. Clinical trials with human beings are planned to start in 2025.

Paltech SAS is assisted by Épron Quievy & Associés on a day-to-day basis with Étienne Épron, partner and Cassandra Gimbert, associate.

More info on Paltech